|Dr. Gregory M. Weinhoff||Chief Financial Officer||561.03k||N/A||1971|
|Dr. Pavan Cheruvu||Chief Exec. Officer||N/A||N/A||N/A|
|Mr. Michael Adasczik||Principal Accounting Officer||N/A||N/A||1974|
|Mr. Jonathan Neely||Head of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Marianne L. Romeo Dinsmore||Head of Global Transactions & Risk Management||N/A||N/A||1968|
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Axovant Sciences Ltd.’s ISS Governance QualityScore as of April 1, 2018 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 3; Compensation: 10.